final resolution2025-08-26active
Arzneimittel-Richtlinie/Anlage XII: Lazertinib (nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), Kombination mit Amivantamab) – Therapiekosten
Open official decision page ↗
G-BA source · retrieved 2026-08-05
Decision orientation
What the G-BA did
3 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
- Decision date
- 2025-08-26
- Effective
- 28.08.2025
- Action type
- final resolution
- Committee
- Arzneimittel
Case context
Listed normative targets
directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V
A listed target is not treated as a new directive version unless an official version source exists.
Official document package